Systems and methods for use and regeneration of chromatography - Patents.com

Abstract

An embodiment of the present disclosure relates to a method of regenerating a hydrophobic interaction chromatography column to which a load mass has been applied, comprising passing one or more column volumes of an alkaline solution exhibiting a pH between about 10 and about 14 and a conductivity between 0.5 mS / cm and about 10 mS / cm through a hydrophobic interaction medium in the column, thereby removing substances bound to the hydrophobic interaction medium. In some cases, the alkaline solution can include, for example, sodium hydroxide at a concentration between about 0.1 mM and 10 mM.

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of U.S. Provisional Patent Application No. 62 / 905,033, filed September 24, 2019, and U.S. Provisional Patent Application No. 62 / 958,899, filed January 9, 2020, both of which are incorporated by reference in their entireties herein. [Background technology]

[0002] Field of Disclosure

[0002] The present disclosure relates to systems, methods, and solutions for the use and regeneration of chromatography media. Some aspects of the present disclosure relate to systems and methods incorporating a single-step hydrophobic interaction chromatography media regeneration solution.

[0003] Introduction

[0003] Chromatography is a widely used category of processes that can be performed to separate components of a mixture. Certain types of chromatography can be performed in drug product preparation processes (e.g., separating, collecting, isolating, purifying, polishing, etc., of molecules for use in drug products). Some molecules of interest (e.g., polypeptides, polyribonucleotides, etc.) may need to be purified from the host cell material in which they were produced. Separating or purifying the molecule of interest using chromatography can reduce, remove, or separate host cell proteins (e.g., lipases), host cell material (e.g., cell debris), and other impurities that may otherwise be co-purified with the molecule of interest.

[0004] Chromatography may involve the use of a stationary phase that includes a medium configured to aid in the separation of components of a mobile phase passing through the stationary phase. For example, hydrophobic interaction chromatography (HIC) may separate molecules (e.g., polypeptides, polynucleotides, etc.) according to differences in surface hydrophobicity by using a reversible interaction between the molecules and the hydrophobic surface of the HIC medium in the stationary phase. The interaction between the molecules and the hydrophobic surface of the HIC medium may be affected, for example, by salts in a running buffer. A load mass having a high salt concentration may be loaded into the HIC device, where the high salt concentration promotes interactions between the HIC medium in the device and the molecules in the mixture. A solution of reduced ionic strength (e.g., a buffer) may then be flowed through the HIC device, reversing the hydrophobic interactions between the HIC medium and the molecules. The least hydrophobic molecules can be eluted first, and the most hydrophobic molecules can be eluted last, since they require a larger decrease in salt concentration to reverse the hydrophobic interaction with the HIC medium.

[0005]

[0005] In some cases, the HIC media is reusable for multiple chromatography cycles. To maintain the effectiveness, quality, and cleanliness of the HIC media, prevent contamination between cycles, increase the life of the HIC media, prevent the accumulation of impurities, and / or otherwise meet or exceed operating standards (e.g., internal laboratory or organization operating standards, or operating standards mandated by a regulatory agency), methods for regenerating the HIC media may be used to remove residual material from the HIC media after performing an HIC cycle. Summary of the Invention

[0006]

[0006] Aspects of the present disclosure relate to regenerating a chromatography column. In one aspect, the present disclosure relates to a method of regenerating a hydrophobic interaction chromatography column to which a load mass has been applied. The method may include passing one or more column volumes of an alkaline solution through a hydrophobic interaction media in the column, the alkaline solution exhibiting a pH between about 10 and about 14 and a conductivity between 0.5 mS / cm and about 10 mS / cm, and material bound to the hydrophobic interaction media is removed. The alkaline solution may include one of sodium hydroxide, potassium hydroxide, calcium hydroxide, magnesium hydroxide, or Tris; the alkaline solution may exhibit a conductivity between about 0.8 mS / cm and about 1.6 mS / cm, and / or the alkaline solution may include a total dissolved salt concentration between about 0.1 mM and about 10 mM.

[0007]

[0007] After removal of the material bound to the hydrophobic interaction medium, less than 1.0% of the loaded mass may remain bound to the hydrophobic interaction medium as a residual mass. The material removed from the medium may include host cell proteins, suggested proteins, lipids, polypeptide fragments, biomolecules, or nucleic acids. The material removed from the medium may, in some embodiments, be free of bacteria or fungi. The method may, in some embodiments, not include contacting the hydrophobic interaction medium with a chaotropic agent or an organic solvent. The step of passing one or more column volumes of an alkaline solution through the hydrophobic interaction medium in the column takes from about 10 minutes to about 1 hour.

[0008]

[0008] In another aspect, the disclosure provides a method for regenerating a chromatography column to which a load mass has been applied, comprising passing one or more column volumes of an alkaline solution through a hydrophobic interaction medium in the column, the alkaline solution comprising sodium hydroxide at a total dissolved concentration of between about 0.5 mM and about 50 mM, and removing material bound to the medium. The medium may comprise a matrix comprising a ligand having between 2 and 10 hydrocarbons in an aliphatic or aromatic configuration. The ligand may be present in the medium at a density of between about 20 and about 30 μmol per ml of medium. In other examples, the medium may not include a ligand having 30 or more hydrocarbons; the chromatography column may not be used in a mixed-mode chromatography process; and / or the medium may include a matrix comprising cross-linked agarose and a phenyl ligand. In other examples, the method may not include contacting the medium with alcohol, ethylene glycol, or sodium chloride. The method may further include passing one or more column volumes of a chaotropic agent through the column after passing one or more column volumes of the alkaline solution through the column, the chaotropic agent being one of 6N guanidine hydrochloride or 8N urea. The method may further include contacting the column with a storage buffer comprising sodium hydroxide at a total dissolved concentration of between about 0.05M and about 0.15M. The method may also further include applying a first load mass to the chromatography column and applying a second load mass to the chromatography column, and does not include cleaning the chromatography column.

[0009] In another aspect, the disclosure relates to a method of identifying a concentration of an alkaline solution for a hydrophobic interaction chromatography column regenerating solution, comprising passing a volume of a first solution through a hydrophobic interaction medium in a column, where in the first solution includes water and a concentration of an alkaline solution beginning from about 0N and increasing at an approximately constant rate to a maximum concentration; passing a volume of a second solution through the hydrophobic interaction medium, where in the second solution includes water and a concentration of an alkaline solution beginning from the maximum concentration and decreasing at an approximately constant rate to about 0N; and identifying a portion of the first or second solution that removes material bound to the hydrophobic interaction medium as it passes through the hydrophobic interaction medium. The alkaline solution may include sodium hydroxide and may have a maximum concentration of about 1N. In another example, the volume of the first solution and the volume of the second solution are each about 20 column volumes.

[0010] In another aspect, the disclosure includes predicting, evaluating, or comparing the utility and regeneration of various chromatography resins. In some examples, a method for evaluating a chromatography protocol includes adding a load mass containing a target molecule to a volume of a chromatography medium in a filter plate well, and collecting a flowthrough from the filter plate well, where the load mass indicates a protocol pH; adding aliquots of a buffer containing the chromatography medium to obtain an eluate from the chromatography medium, where the buffer indicates a buffer pH, a concentration of a kosmotropic salt decreases linearly over the plurality of aliquots, and a first amount of the target molecule is contained in the combined flowthrough and eluate; adding a second solution to the chromatography medium to extract a second amount of the target molecule from the chromatography medium; and adding a chaotropic agent to the chromatography medium to extract a third amount of the target molecule from the chromatography medium. [Brief description of the drawings]

[0011]

[0011] The accompanying figures are incorporated in and constitute a part of this specification, illustrate various exemplary embodiments, and together with this specification, serve to explain the principles of the disclosed embodiments. Any feature (e.g., composition, formulation, method, etc.) of an embodiment or example described herein may be combined with any other embodiment or example, and all such combinations are included in this disclosure. Furthermore, the described systems and methods are not limited to any one aspect or embodiment thereof, nor are they limited to any combination or permutation of such aspects and embodiments. For the sake of brevity, certain permutations and combinations are not separately discussed and / or illustrated herein.

[0012] [Figure 1] FIG. 1 illustrates, in flow chart form, an exemplary method according to an aspect of the present disclosure.

[0013] [Diagram 2] FIG. 2 shows a blot analysis of a chromatography column in various states of use according to an embodiment of the present disclosure.

[0014] [Diagram 3] FIG. 3 shows a blot analysis of a chromatography column in various states of use according to an embodiment of the present disclosure.

[0015] [Figure 4] FIG. 4 shows an overlay of chromatography data from multiple processes according to an embodiment of the present disclosure.

[0016] [Diagram 5] FIG. 5 shows a blot analysis of a chromatography column in various states of use according to an embodiment of the present disclosure.

[0017] [Figure 6] FIG. 6 shows a comparison of a column containing a hydrophobic interaction medium that has been subjected to multiple hydrophobic interaction chromatography cycles with a column containing unused hydrophobic interaction medium according to an embodiment of the present disclosure.

[0018] [Figure 7A] 7A and 7B show chromatograms of a regeneration process following hydrophobic interaction chromatography, the process including the use of reverse osmosis deionized water, according to an embodiment of the present disclosure. [Figure 7B]7A and 7B show chromatograms of a regeneration process following hydrophobic interaction chromatography, the process including the use of reverse osmosis deionized water, according to an embodiment of the present disclosure.

[0019] [Figure 8A] 8A and 8B show further chromatograms of the regeneration process following hydrophobic interaction chromatography. [Figure 8B] 8A and 8B show further chromatograms of the regeneration process following hydrophobic interaction chromatography.

[0020] [Figure 9] FIG. 9 shows a chromatogram of the regeneration process using guanidine HCl solution according to an embodiment of the present disclosure.

[0021] [Figure 10A] FIG. 10A shows a chromatogram of a process involving multiple regenerant solutions according to an embodiment of the present disclosure. [Figure 10B] FIG. 10B shows an enlarged image of a portion of the chromatogram in FIG. 10A.

[0022] [Figure 11] FIG. 11 shows a chromatogram of a process in which a sodium hydroxide solution having a gradually increasing / gradually decreasing concentration is introduced into the column in accordance with an embodiment of the present disclosure.

[0023] [Figure 12]FIG. 12 shows overlaid chromatograms of multiple two-solution column regeneration processes according to an embodiment of the present disclosure.

[0024] [Figure 13A] 13A and 13B are visual depictions of statistical analyses of various peaks of a chromatogram showing the regeneration process according to an embodiment of the present disclosure. [Figure 13B] 13A and 13B are visual depictions of statistical analyses of various peaks of a chromatogram showing the regeneration process according to an embodiment of the present disclosure.

[0025] [Figure 14] FIG. 14 shows overlaid chromatograms of multiple two-solution column regeneration processes involving either sodium hydroxide or sodium chloride and guanidine HCl, according to an embodiment of the present disclosure.

[0026] [Figure 15] FIG. 15 shows three chromatography columns having solutions applied thereto, according to an embodiment of the present disclosure.

[0027] [Figure 16] FIG. 16 shows a graph of guanidine HCl stripping solution peak area as a function of sodium hydroxide concentration, in accordance with an embodiment of the present disclosure.

[0028] [Figure 17] 17 and 18 show chromatograms of a control regeneration process and an experimental regeneration process, each involving multiple regeneration solutions, according to an embodiment of the present disclosure. [Figure 18]17 and 18 show chromatograms of a control regeneration process and an experimental regeneration process, each involving multiple regeneration solutions, according to an embodiment of the present disclosure.

[0029] [Figure 19] FIG. 19 shows a series of chromatograms of hydrophobic interaction chromatography runs for purifying different monoclonal antibodies according to an embodiment of the present disclosure.

[0030] [Figure 20A-B] 20A-20C show chromatograms generated using a protocol involving three different hydrophobic interaction chromatography media according to an embodiment of the present disclosure. [Figure 20C] 20A-20C show chromatograms generated using a protocol involving three different hydrophobic interaction chromatography media according to an embodiment of the present disclosure.

[0031] [Figure 21A-B] 21A and 21B show plots of boundary functions developed through analysis of data generated during high-throughput screening and full-scale chromatography runs, according to embodiments of the present disclosure.

[0032] [Figure 22] FIG. 22 illustrates an example dynamic prediction model in accordance with an aspect of the present disclosure.

[0033] [Figure 23A-B]23A-26C show chromatograms for a first target molecule generated using a number of hydrophobic interaction chromatography media, pH parameters, and stripping solutions according to embodiments of the present disclosure. [Figure 23C] 23A-26C show chromatograms for a first target molecule generated using a number of hydrophobic interaction chromatography media, pH parameters, and stripping solutions according to embodiments of the present disclosure. [Fig. 24A-B] 23A-26C show chromatograms for a first target molecule generated using a number of hydrophobic interaction chromatography media, pH parameters, and stripping solutions according to embodiments of the present disclosure. [Figure 24C] 23A-26C show chromatograms for a first target molecule generated using a number of hydrophobic interaction chromatography media, pH parameters, and stripping solutions according to embodiments of the present disclosure. [Fig. 25A-B] 23A-26C show chromatograms for a first target molecule generated using a number of hydrophobic interaction chromatography media, pH parameters, and stripping solutions according to embodiments of the present disclosure. [Figure 25C] 23A-26C show chromatograms for a first target molecule generated using a number of hydrophobic interaction chromatography media, pH parameters, and stripping solutions according to embodiments of the present disclosure. [Figure 26A-B] 23A-26C show chromatograms for a first target molecule generated using a number of hydrophobic interaction chromatography media, pH parameters, and stripping solutions according to embodiments of the present disclosure. [Figure 26C] 23A-26C show chromatograms for a first target molecule generated using a number of hydrophobic interaction chromatography media, pH parameters, and stripping solutions according to embodiments of the present disclosure.

[0034] [Figure 27A-B] 27A-28D show chromatograms for a second target molecule generated using a number of hydrophobic interaction chromatography media, pH parameters, and stripping solutions according to embodiments of the present disclosure. [Figure 27C-D] 27A-28D show chromatograms for a second target molecule generated using a number of hydrophobic interaction chromatography media, pH parameters, and stripping solutions according to embodiments of the present disclosure. [Fig. 28A-B] 27A-28D show chromatograms for a second target molecule generated using a number of hydrophobic interaction chromatography media, pH parameters, and stripping solutions according to embodiments of the present disclosure. [Fig. 28C-D] 27A-28D show chromatograms for a second target molecule generated using a number of hydrophobic interaction chromatography media, pH parameters, and stripping solutions according to embodiments of the present disclosure. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0035]

[0035] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those of ordinary skill in the art to which this disclosure belongs. In the practice or testing of this disclosure, any suitable methods and materials (e.g., similar or equivalent to those described herein) may be used, but specific methods are described herein. All publications mentioned are incorporated herein by reference.

[0036]

[0036] As used herein, the terms "comprises", "comprising" or any variation thereof are intended to include a non-exclusive inclusion, such that a process, method, article, or apparatus that includes a list of elements does not include only those elements, but may include other elements not expressly listed or inherent in such process, method, article, or apparatus. The term "exemplary" is used in the sense of "example" rather than "ideal." With respect to the terms "for example" and "such as" and their grammatical equivalents, it is understood that the phrase "and without limitation" follows, unless expressly stated otherwise.

[0037]

[0037] As used herein, the term "about" is meant to take into account variations due to experimental error. When applied to a numerical value, the term "about" may indicate a variation of + / - 5% from the disclosed numerical value unless a different variation is specified. As used herein, the singular forms "a", "an" and "the" include plural referents unless the context clearly indicates otherwise. Furthermore, all ranges are understood to include the endpoints, for example, 1 centimeter (cm) to 5 cm includes the length of 1 cm, 5 cm, and all distances between 1 cm and 5 cm.

[0038]

[0038] All numerical values ​​disclosed herein (including all disclosed values, limits, and ranges) can have a variation of + / - 5% from the disclosed numerical value, unless a different variation is specified.

[0039]

[0039] The term "polypeptide" as used herein refers to any amino acid polymer having more than about 20 amino acids covalently linked through amide bonds. A protein contains one or more amino acid polymer chains (e.g., polypeptides). Thus, a polypeptide may be a protein, and a protein may contain multiple polypeptides to form one functional biomolecule.

[0040]

[0040] Post-translational modifications can modify or alter the structure of a polypeptide. For example, in some proteins, disulfide bridges (e.g., S-S bonds between cysteine ​​residues) can be formed after translation. Some disulfide bridges are essential for the proper structure, function, and interaction of polypeptides, immunoglobulins, proteins, cofactors, substrates, etc. In addition to disulfide bond formation, proteins may be subject to other post-translational modifications, such as lipidation (e.g., myristoylation, palmitoylation, farnesoylation, geranylgeranylation, and glycosylphosphatidylinositol (GPI) anchor formation), alkylation (e.g., methylation), acylation, amidation, glycosylation (e.g., addition of glycosyl groups at arginine, asparagine, cysteine, hydroxylysine, serine, threonine, tyrosine, and / or tryptophan), and phosphorylation (i.e., addition of phosphate groups to serine, threonine, tyrosine, and / or histidine). Post-translational modifications may affect hydrophobicity, electrostatic surface properties, or other properties that determine surface-surface interactions involving polypeptides.

[0041]

[0041] As used herein, the term "protein" includes biological therapeutic proteins, recombinant proteins used in research or therapy, trap proteins and other Fc fusion proteins, chimeric proteins, antibodies, monoclonal antibodies, human antibodies, bispecific antibodies, antibody fragments, antibody-like molecules, nanobodies, recombinant antibody chimeras, cytokines, chemokines, peptide hormones, and the like. Proteins of interest (POI) can include any polypeptide or protein that is desired to be isolated, purified, or otherwise prepared. POI can include polypeptides produced by cells, including antibodies.

[0042]

[0042] The term "antibody" as used herein includes immunoglobulins composed of four polypeptide chains, two heavy (H) chains and two light (L) chains interconnected by disulfide bonds. Typically, antibodies have a molecular weight of more than 100 kDa, for example between 130 kDa and 200 kDa, for example about 140 kDa, 145 kDa, 150 kDa, 155 kDa, or 160 kDa. Each heavy chain comprises a heavy chain variable region (abbreviated herein as HCVR or VH) and a heavy chain constant region. The heavy chain constant region comprises three domains, CH1, CH2, and CH3. Each light chain comprises a light chain variable region (abbreviated herein as LCVR or VL) and a light chain constant region. The light chain constant region comprises one domain, CL. The VH and VL regions can be further divided into regions of hypervariability, termed complementarity determining regions (CDRs), interspersed with more conserved regions, termed framework regions (FRs). Each VH and VL is composed of three CDRs and four FRs, arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4 (heavy chain CDRs may be abbreviated as HCDR1, HCDR2 and HCDR3; light chain CDRs may be abbreviated as LCDR1, LCDR2 and LCDR3).

[0043] For example, the immunoglobulin class called immunoglobulin G (IgG) is common in human serum and contains four polypeptide chains, two light chains and two heavy chains. Each light chain is linked to one heavy chain through one cysteine ​​disulfide bond, and the two heavy chains are linked to each other through two cysteine ​​disulfide bonds. Other classes of human immunoglobulins include IgA, IgM, IgD, and IgE. In the case of IgG, there are four subclasses, IgG1, IgG2, IgG3, and IgG4. Each subclass differs in the constant region and, as a result, may have different effector functions. In some embodiments described herein, the POI may include a target polypeptide that includes IgG. In at least one embodiment, the target polypeptide includes IgG4.

[0044]

[0044] The term "antibody", as used herein, also includes antigen-binding fragments of full-length antibody molecules. The terms "antigen-binding portion" of an antibody, "antigen-binding fragment" of an antibody, and the like, as used herein, include any naturally occurring, enzymatically obtainable, synthetic, or genetically engineered polypeptide or glycoprotein that specifically binds to an antigen to form a complex. Antigen-binding fragments of antibodies can be obtained from full-length antibody molecules, for example, using any suitable standard technique, such as proteolytic digestion, or recombinant genetic engineering techniques involving the manipulation and expression of DNA encoding antibody variable domains and, optionally, constant domains. Such DNA is known and / or readily available, for example, from commercial sources, DNA libraries (including, for example, phage-antibody libraries), or can be synthesized. The DNA can be sequenced and chemically engineered, or can be engineered using molecular biology techniques, for example, by arranging one or more variable and / or constant domains in the appropriate configuration, or by introducing codons, generating cysteine ​​residues, modifying, adding or deleting amino acids, and the like.

[0045] Recombinant cell-based production systems, such as insect baculovirus systems, yeast systems (e.g. Pichia spp.), or mammalian systems (e.g. CHO cells and CHO derivatives such as CHO-K1 cells), may be used to produce target molecules (e.g. target polypeptides / antibodies). The term "cell" includes any cell suitable for expressing recombinant nucleic acid sequences. Cells include prokaryotic and eukaryotic (unicellular or multicellular), bacterial cells (e.g. strains of E. coli, Bacillus spp., Streptomyces spp.), mycobacterial cells, fungal cells, yeast cells (e.g. S. cerevisiae, S. pombe, P. pastoris, P. methanolica, etc.), plant cells, insect cells (e.g. SF-9, SF-21, baculovirus-infected insect cells, Trichoplusiani, etc.), non-human animal cells, human cells, or cell fusions, such as hybridomas or quadromas. In some embodiments, the cells may be human, monkey, ape, hamster, rat, or mouse cells. In some embodiments, the cell may be a eukaryotic cell and may be selected from the following cells: CHO (e.g., CHO K1, DXB-11 CHO, Veggie-CHO), COS (e.g., COS-7), retinal cells, Vero, CV1, kidney (e.g., HEK293, 293 EBNA, MSR 293, MDCK, HaK, BHK), HeLa, HepG2, WI38, MRC 5, Colo205, HB 8065, HL-60, (e.g., BHK21), Jurkat, Daudi, A431 (epithelial), CV-1, U937, 3T3, L cells, C127 cells, SP2 / 0, NS-0, MMT 060562, Sertoli cells, BRL 3A cells, HT1080 cells, myeloma cells, tumor cells, and cells derived from the aforementioned cells. In some embodiments, the cells may contain one or more viral genes, for example, retinal cells expressing viral genes (e.g., PER.C6 TM The cell may be a human cell.

[0046]

[0046] The term "target molecule" may be used herein to refer to a target polypeptide (e.g., an antibody, an antibody fragment, or other protein or protein fragment) or other molecule (e.g., an adeno-associated virus (AAV) or other molecule for therapeutic use) that is intended to be produced, isolated, purified, and / or included in a pharmaceutical product. Methods according to the present disclosure may refer to a target polypeptide, but they may also be applicable to other target molecules. For example, AAV may be prepared according to a suitable method (e.g., depth filtration, affinity chromatography, etc.), and a mixture containing AAV may be subjected to a method according to the present disclosure. Before or after one or more methods of the present disclosure, the mixture containing AAV may be subjected to further treatment (e.g., removal of "empty cassettes" or AAV that do not contain a target sequence).

[0047] In some embodiments, the target molecule is an antibody, a human antibody, a humanized antibody, a chimeric antibody, a monoclonal antibody, a multispecific antibody, a bispecific antibody, an antigen-binding antibody fragment, a single chain antibody, a diabody, a triabody or a tetrabody, a Fab fragment or a F(ab')2 fragment, an IgD antibody, an IgE antibody, an IgM antibody, an IgG antibody, an IgG1 antibody, an IgG2 antibody, an IgG3 antibody, or an IgG4 antibody. In one embodiment, the antibody is an IgG1 antibody. In one embodiment, the antibody is an IgG2 antibody. In one embodiment, the antibody is an IgG4 antibody. In one embodiment, the antibody is a chimeric IgG2 / IgG4 antibody. In one embodiment, the antibody is a chimeric IgG2 / IgG1 antibody. In one embodiment, the antibody is a chimeric IgG2 / IgG1 / IgG4 antibody.

[0048] In some embodiments, the targeting molecule (e.g., an antibody) is an anti-programmed cell death 1 antibody (e.g., an anti-PD1 antibody as described in U.S. Patent Application Publication No. US2015 / 0203579A1), an anti-programmed cell death ligand 1 (e.g., an anti-PD-L1 antibody as described in U.S. Patent Application Publication No. US2015 / 0203580A1), an anti-Dll4 antibody, an anti-angiopoietin-2 antibody (e.g., an anti-ANG2 antibody as described in U.S. Patent No. 9,402,898), an anti-angiopoietin-like 3 antibody (e.g., an anti-IL-1 antibody as described in U.S. Patent Application Publication No. US2015 / 0203579A1), an anti-IL-1 antibody (e.g., an anti-IL-2 antibody as described in U.S. Patent Application Publication No. US2015 / 0203580A1), an anti-IL-1 antibody (e.g., an anti-IL-2 antibody as described in U.S. Patent Application Publication No. US2015 / 0203580A1), an anti-IL-1 antibody (e.g., an anti-IL-1 ... No. 9,302,015), anti-complement 5 antibodies (e.g., anti-C5 antibodies as described in U.S. Patent Application Publication No. US2015 / 0313194A1), anti-TNF antibodies, anti-epidermal growth factor receptor antibodies (e.g., anti-EGFR antibodies as described in U.S. Patent No. 9,132,192), anti-AngPtl3 antibodies as described in U.S. Patent No. 9,265,827, anti-Prolactin Receptor antibodies (e.g., anti-PDGFR antibodies as described in U.S. Patent No. 9,265,827, anti-Prolactin Receptor antibodies (e.g., anti-PRLR antibodies as described in U.S. Patent No. 9,302,015), anti-TNF antibodies, anti-Epidermal Growth Factor Receptor antibodies (e.g., anti-EGFR antibodies as described in U.S. Patent No. 9,132,192, or anti-EGFRvIII antibodies as described in U.S. Patent Application Publication No. US2015 / 0259423A1), anti-proprotein convertase subtilisin kexin-9 antibodies (e.g., anti-PCSK9 antibodies as described in U.S. Patent Application Publication No. US2014 / 0044730A1), anti-growth and differentiation factor-8 antibodies (e.g., anti-GDF8 antibodies, also known as anti-myostatin antibodies, as described in U.S. Patent Nos. 8,871,209 or 9,260,515), anti-glucagon receptor agonists (e.g., anti-glucagon receptor agonists ... Nos. 8,735,095 and 8,945,559; anti-IL-4R antibodies; anti-IL-5R antibodies; anti-IL-6R antibodies; anti-IL-7R antibodies; anti-IL-8R antibodies; anti-IL-9R antibodies;No. 880), anti-interleukin 33 (e.g., anti-IL33 antibodies as described in U.S. Patent Application Publication No. US2014 / 0271658A1 or US2014 / 0271642A1), anti-respiratory syncytial virus antibodies (e.g., anti-RSV antibodies as described in U.S. Patent Application Publication No. US2014 / 0271653A1), anti-surface antigen cluster 3 (e.g., anti-IL6R antibodies as described in U.S. Patent Application Publication No. US2014 / 0088295A1 and Nos. 2014 / 0088295A1 and 20150266966A1, and U.S. Patent Application No. 62 / 222,605), anti-cluster of chromosome 20 (e.g., anti-CD20 antibodies as described in U.S. Patent Application Publication Nos. US2014 / 0088295A1 and US20150266966A1, and U.S. Patent No. 7,879,984), anti-cluster of chromosome 48 (e.g., anti-CD48 antibodies as described in U.S. Patent No. 9,228,014), anti-Fel d1 antibodies (e.g., as described in U.S. Pat. No. 9,079,948), anti-Middle East Respiratory Syndrome virus (e.g., anti-MERS antibodies), anti-Ebola virus antibodies (e.g., Regeneron's REGN-EB3), anti-CD19 antibodies, anti-CD28 antibodies, anti-IL1 antibodies, anti-IL2 antibodies, anti-IL3 antibodies, anti-IL4 antibodies, anti-IL5 antibodies, anti-IL6 antibodies, anti-IL7 antibodies, anti-Erb3 antibodies, anti-Zika virus antibodies, anti-lymphocyte activation gene 3 (e.g., anti-LAG3 antibodies or anti-CD223 antibodies), and anti-activin A antibodies. Each of the U.S. patents and U.S. patent publications referred to in this paragraph is incorporated herein by reference in its entirety.

[0049] In some embodiments, the targeting molecule (e.g., a bispecific antibody) is selected from the group consisting of an anti-CD3x anti-CD20 bispecific antibody, an anti-CD3x anti-mucin 16 bispecific antibody, and an anti-CD3x anti-prostate specific membrane antigen bispecific antibody. In some embodiments, the targeting molecule is selected from the group consisting of alirocumab, sarilumab, fasinumab, nesbacumab, dupilumab, trevogrumab, evinacumab, and rinukumaab.

[0050] In some embodiments, the target molecule is a recombinant protein (e.g., an Fc fusion protein) that contains an Fc portion and another domain. In some embodiments, the Fc fusion protein is a receptor Fc fusion protein, which contains one or more extracellular domains of a receptor coupled to an Fc portion. In some embodiments, the Fc portion comprises a hinge region followed by the CH2 and CH3 domains of IgG. In some embodiments, the receptor Fc fusion protein contains two or more separate receptor chains that bind either one ligand or multiple ligands. For example, the Fc fusion protein is a TRAP protein, such as IL-1 trap (e.g., rilonacept, which contains the IL-1RAcP ligand binding domain fused to the Il-1R1 extracellular domain fused to the Fc of hIgG1; see U.S. Patent No. 6,927,004, which is incorporated herein by reference in its entirety), or VEGF trap (e.g., aflibercept or dibuaflibercept, which contains the Ig domain 2 of the VEGF receptor Flt1 fused to the Ig domain 3 of the VEGF receptor Flk1 fused to the Fc of hIgG1; see U.S. Patent Nos. 7,087,411 and 7,279,159, which are both incorporated herein by reference in their entirety). In other embodiments, the Fc fusion protein is a ScFv-Fc fusion protein, which contains one or more of one or more antigen binding domains, such as the variable heavy and variable light fragments of an antibody coupled to the Fc portion.

[0051]

[0051] Embodiments of the present disclosure may be used in the preparation of various pharmaceutical products or in the development of methods for purifying various pharmaceutical products. In some embodiments, the present disclosure may be useful in the preparation or purification of pharmaceutical products that include antigen-binding molecules or AAVs. In some aspects, embodiments of the present disclosure may be suitable for use in the preparation of a pharmaceutical product that includes a component such as, for example, aflibercept, alirocumab, abicipar pegol, bevacizumab, brolucizumab, conbercept, duplimab, evolocumab, tocilizumab, certolizumab, abatacept, rituximab, infliximab, ranibizumab, sarilumab, adalimumab, anakinra, trastuzumab, pegfilgrastim, interferon beta 1a, insulin glargine [rDNA origin], epoetin alfa, darbepoetin, filigrastim, golimumab, etanercept, an antigen-binding fragment of any of the above, or a combination of such binding domains, such as a bispecific antibody against VEGF or angiopoietin-2, among others.

[0052]

[0052] The term "hydrophobic interaction media" or "HIC media" refers to a combination of a support structure and a hydrophobic moiety, the hydrophobic moiety being immobilized on the support structure. The media may be in the form of a chromatographic medium, e.g., beads or other particles held in a packed bed column format, a membrane format, or any format capable of accommodating a liquid containing the protein of interest and contaminants. Thus, support structures include agarose beads (e.g., sepharose), silica beads, cellulosic membranes, cellulosic beads, hydrophilic polymer beads, resins, etc. The hydrophobic moiety binds to hydrophobic molecules and the hydrophobic surface of proteins. The degree of hydrophobicity of the media can be adjusted by the selection of the hydrophobic moiety. Hydrophobic interaction media are used in a process known as hydrophobic interaction chromatography (HIC) to separate target molecules, such as proteins or other molecules of interest, from product and process related contaminants. When target molecules are produced in and / or purified from host cells, some product and process related components that must ultimately be separated from the target molecule are referred to as host cell proteins (HCPs) and cellular debris. In some examples, a mixture containing the target molecule and other components is applied to the HIC medium in a buffer designed to promote binding of hydrophobic groups in the target molecule to the hydrophobic moieties of the HIC medium. Such a mixture may be referred to as a "load mass."HIC exploits hydrophobic differences between target molecule(s) and impurities to produce separation during the load, wash, or regeneration phase. Often, target molecules are separated in the flow through, while impurities are bound to the HIC medium. HIC may also be operated in a manner in which target molecules bind to the HIC medium, while HCPs and cell debris cannot bind and flow through. The present disclosure is applicable in either case (whether or not the target molecule is bound to the hydrophobic interaction moiety).

[0053]

[0053] The HIC medium may be periodically stripped or regenerated after use in the purification / collection of a target molecule. As used herein, the terms "stripping" and "regenerating" are used interchangeably and / or in combination to refer to a process configured to remove any residual components of a load mass from the HIC medium after a purification cycle and prepare the HIC medium for a subsequent purification cycle. For example, the HIC device may be used to separate or purify a molecule of interest from a load mass containing host cell material (e.g., host cell debris, host cell proteins, etc.), and after the molecule of interest is eluted from the HIC device, the HIC medium may be regenerated to remove residual materials (e.g., host cell material, host cell proteins, lipids, residual polypeptides, aggregated proteins, nucleic acids, biomolecules, etc.) from the HIC medium and prepare the HIC medium for use in purifying a molecule of interest from another load mass. In some embodiments, regeneration of the HIC medium may include disrupting hydrophobic interactions between residual host cell material and / or target molecules and the HIC medium and / or denaturing the residual host cell material. Regeneration may be performed between HIC cycles to "reset" the HIC medium without the need for a longer cleaning process. In some embodiments, regeneration may be performed between HIC cycles to prevent or reduce discoloration of the HIC medium over time. In some embodiments, a regeneration process according to the present disclosure may be performed for, for example, about 5 minutes to about 1 hour, for example, about 10 minutes to about 1 hour, about 10 minutes to about 45 minutes, or about 10 minutes to about 30 minutes. Preferably, regeneration of the HIC medium may be completed without subjecting the HIC medium to more robust cleaning solutions that may have undesirable effects or raise additional concerns. The regeneration process may be configured without a specific emphasis on the removal of, for example, bacteria, fungi, or other microorganisms from the chromatographic medium.

[0054]

[0054] "Stripping" and "regeneration" may be distinguished from, for example, "cleaning" of chromatographic media. Cleaning may include processes intended for complete disinfection and / or decontamination of chromatographic media, chromatographic equipment, and / or experimental settings. For example, a cleaning process may include the use of antibiotic, antifungal, or other antimicrobial solutions, other disinfecting solutions, sterilization methods, etc., in concentrations and amounts intended for sanitizing and / or sterilizing the chromatographic media or chromatographic equipment. In contrast, regeneration may in some cases include the use of solutions with antimicrobial properties, but the main intent of regeneration may be to remove residual components of the load mass from the chromatographic media after the purification process. In some embodiments, additional protection or treatment may be required during and / or after the cleaning process to ensure that subsequent chromatographic cycles are not affected by the disinfecting, sanitizing, antimicrobial, or antibiotic solutions used during the cleaning process. In many cases, the cleaning process may be longer than the regeneration process (e.g., more than about an hour).

[0055]

[0055] Separation of molecules in an HIC medium can be achieved, for example, by exposing the HIC medium to a loading mass having a high salt concentration to increase hydrophobic interactions between the HIC medium and the target molecules in the loading mass, and then passing a volume of a solution (e.g., a buffer) having a decreased or decreasing salt concentration through the HIC medium to reverse the hydrophobic interactions. Thus, it is conventionally understood that in low- or no-salt conditions, less material binds to the HIC medium. Surprisingly, however, it has been discovered that certain types of HIC medium exhibit increased binding (e.g., hydrophobic interactions) to residual material (e.g., host cell proteins) under salt-free conditions. Furthermore, some proteins (e.g., monoclonal antibodies) can be bound to certain types of HIC medium (e.g., Capto TM It has been found that proteins can be denatured on HIC media (High Sub) (GE Healthcare Life Sciences). Although proteins can return to their native configurations once eluted from the HIC media, such proteins in a denatured state may not be removed from the HIC media by regeneration procedures involving, for example, reverse osmosis deionized water (RODI), 1N sodium hydroxide, and / or 20% ethanol. In some cases, elution of molecules from the HIC media is hypothesized to be pH and / or conductivity dependent.

[0056] Aspects of the present disclosure relate to the evaluation of chromatography media for their usefulness, including regeneration solutions and ease of regeneration.

[0057]

[0057] In some embodiments of the present disclosure, the regeneration solution may be an alkaline solution. In some embodiments of the present disclosure, it is contemplated that high pH may be a driving factor in the effectiveness of the regeneration solution; however, it is further contemplated that in some cases, the effectiveness of high pH may be offset by high ionic strength. Thus, in some embodiments, the effectiveness of the regeneration solution may be driven by high pH combined with low but non-zero conductivity (see, e.g., Example 14 discussed below). For example, in some embodiments, the regeneration solution may exhibit a pH between about 8 and about 14, e.g., about 10 and about 14. In some embodiments, the regeneration solution may exhibit a generally low conductivity. For example, in some embodiments, the regeneration solution may exhibit a conductivity of between about 0.5 mS / cm and about 10 mS / cm, e.g., between about 0.5 mS / cm and about 5 mS / cm, between about 5.0 mS / cm and about 10 mS / cm, between about 0.5 mS / cm and about 3 mS / cm, between about 0.5 mS / cm and about 1.6 mS / cm, between about 0.8 mS / cm and about 1.6 mS / cm, about 0.5 mS / cm, about 1.0 mS / cm, about 1.5 mS / cm, about 2.0 mS / cm, about 2.5 mS / cm, about 3 mS / cm, about 3.5 mS / cm, about 4.0 mS / cm, about 4.5 mS / cm, or about 5.0 mS / cm.

[0058] In some embodiments, the regeneration solution can be an alkaline solution containing, for example, sodium hydroxide, potassium hydroxide, calcium hydroxide, magnesium hydroxide, Tris, other alkaline solutions, or combinations thereof at a concentration. In some embodiments, the regeneration solution can be a concentration of between about 0.1 mM and about 50 mM, for example, between about 0.1 mM and about 25 mM, between about 0.1 mM and about 20 mM, between about 0.1 mM and about 15 mM, between about 0.1 mM and about 10 mM, between about 0.1 mM and about 5 mM, between about 0.1 mM and about 2.5 mM, between about 1 mM and about 10 mM, between about 1 mM and about 7 mM, between about 2.5 mM and about 5 mM, or between about The total dissolved salt concentration may be between 2.5 mM and about 7 mM, e.g., about 0.5 mM, about 1 mM, about 1.5 mM, about 2 mM, about 2.5 mM, about 3 mM, about 3.5 mM, about 4 mM, about 4.5 mM, about 5 mM, about 5.5 mM, about 6 mM, about 6.5 mM, about 7 mM, about 7.5 mM, about 8 mM, about 8.5 mM, about 9 mM, about 9.5 mM, about 10 mM, about 15 mM, about 20 mM, or about 25 mM.

[0059]

[0059] In some embodiments, the regeneration solutions according to the present disclosure may be suitable for use in single-step regeneration processes. That is, in some embodiments, a method of regenerating an HIC medium may include contacting the HIC medium with a single solution, where the solution exhibits one or more properties described herein, and after contact with the single solution, less than about 5% of the load mass remains associated with the HIC medium as residual mass. For example, in some embodiments, a method of regenerating an HIC medium may include contacting the HIC medium with a solution exhibiting a pH between about 10 and about 14 and a conductivity between about 0.5 mS / cm and about 10 mS / cm, whereafter less than about 5% of the load mass remains associated with the HIC medium as residual mass. In some embodiments, the residual mass may be less than about 4%, less than about 3%, less than about 2%, or less than about 1% of the load mass.

[0060] The volume of regenerating solution used in accordance with the present disclosure can be any suitable volume. In some embodiments, such as applying a loading mass to a HIC media in a chromatography column, the volume of regenerating solution used in accordance with the present disclosure can be measured in column volumes (CV). In some embodiments, for example, a method of regenerating a HIC media in a chromatography column can include passing at least one CV of regenerating solution through the column. In some embodiments, the method may include passing between about 1 and about 20 column volumes, e.g., between about 1 column volume and about 15 column volumes, between about 1 column volume and about 10 column volumes, between about 1 column volume and about 5 column volumes, between about 3 column volumes and about 17 column volumes, between about 5 column volumes and about 15 column volumes, or between about 5 column volumes and about 10 column volumes, e.g., about 1 column volume, about 2 column volumes, about 3 column volumes, about 4 column volumes, about 5 column volumes, about 6 column volumes, about 7 column volumes, about 8 column volumes, about 9 column volumes, about 10 column volumes, about 12 column volumes, about 14 column volumes, about 16 column volumes, about 18 column volumes, or about 20 column volumes of regeneration solution through the column.

[0061]

[0061] The systems and methods according to the present disclosure may be applicable to a variety of separation media and / or processes. A single system, method, or solution of the present disclosure may share features with more than one aspect described herein. In some exemplary embodiments, the systems and methods according to the present disclosure may be applicable to media and / or processes that separate components of a load mass based entirely or partially on their hydrophobicity, such as HIC, or to media and / or processes that use a combination of hydrophobicity and charge, such as ion exchange / hydrophobic interaction mixed mode chromatography. In some embodiments, one or more regeneration solutions and / or methods disclosed herein may be combined with (e.g., performed before or after) other regeneration solutions and / or methods. For example, a regeneration solution of the present disclosure may be applied to a medium used in mixed mode chromatography to strip the medium of residual mass that interacts with the medium due to hydrophobicity. Another regeneration solution may also be applied to the medium to strip the medium of residual mass that is bound to the medium due to charge.

[0062] In some embodiments, the regeneration solutions and / or methods disclosed herein may be applicable to HIC media having a high degree of hydrophobicity. In some embodiments, the chromatography media that may be used in the solutions and methods according to the present disclosure may include hydrophobic matrices including, for example, cross-linked agarose, polystyrene divinylbenzene, or polymethacrylate. In some embodiments, the matrix may include ligands having between 2 and 10 hydrocarbons in an aliphatic or aromatic configuration. In some embodiments, the matrix does not include ligands having 30 or more hydrocarbons. In some embodiments, for example, the ligands may include phenyl ligands, butyl ligands, or octyl ligands. In some embodiments, the ligands may be present in the media at a density between about 20 and about 30 μmol per ml of media. In some embodiments, the methods and regeneration solutions described herein may be particularly applicable to regenerating HIC media. In some embodiments, the methods and regeneration solutions described herein may be particularly applicable to regenerating HIC media including, for example, Capto TM Phenyl (High Sub), Capto TM Butyl, or Capto TM Octyl medium (GE Healthcare Life Sciences), Phenyl Sepharose (R) Media (GE Healthcare Life Sciences), POROS TM Benzyl and POROS TM Ethyl HIC resin (Thermo Scientific TM ), or TOYOPEARL TMResins may be suitable for use in continuous (multi-column) HIC systems and methods. In some embodiments, the methods and regeneration solutions described herein may be suitable for use in continuous (multi-column) HIC systems and methods, such as those disclosed in International Application No. PCT / US2019 / 040148, filed July 1, 2019, which is incorporated herein by reference. For example, a one-step regeneration solution according to the present disclosure may be used in a multi-column continuous HIC setup, where the efficiency of the one-step regeneration solution may enhance the overall efficiency of the multi-column setup. In some embodiments, the methods and regeneration solutions described herein may be useful in HIC systems and methods, including low- or no-kosmotrope conditions.

[0063] In some embodiments, the regeneration process according to the present disclosure may be carried out without the use of reverse osmosis deionized water (RODI), organic solvents (e.g., ethanol or ethylene glycol), chaotropic agents (e.g., guanidine or urea), sodium chloride, and / or sodium hydroxide at concentrations greater than 50 mM. Advantageously, the regeneration process using the solutions disclosed herein may not require further processes to dispose of, for example, solvents, such as ethanol (e.g., 20% ethanol), and chaotropic agents, such as guanidine and urea (e.g., 6N guanidine or 6N urea). However, in some embodiments, it is contemplated that the regeneration solutions disclosed herein may be used before, after, or in combination with organic solvents (e.g., 20% ethanol) or chaotropic agents (e.g., 6N guanidine or 6N urea).

[0064] In some embodiments, methods according to the present disclosure can include passing a regeneration solution as disclosed herein through the chromatography column prior to contacting the chromatography column with a storage buffer for storage purposes. The storage buffer can include, for example, sodium hydroxide or another salt at a concentration between about 0.05M and about 0.15M.

[0065] In some embodiments, the method according to the present disclosure may include evaluation of various chromatographic media to identify whether one or more chromatographic media present problems with media use or regeneration during purification of a target molecule. Evaluation of chromatographic media according to the present disclosure may include, for example and without limitation, the use of one or more chromatographic media types, maintenance of pH conditions, and target molecules. Advantageously, the method according to the present disclosure may include screening on a smaller scale than typically performed to purify a target molecule, allowing for significant savings in sample volume (e.g., using approximately 1 / 10, 1 / 100, 1 / 500, 1 / 700 or less of the volume of sample required to evaluate a chromatographic medium, e.g., HIC, according to conventional methods). Additionally, multiple purification schemes with different variables (e.g., different combinations and types of media, pH, and / or target molecules) may be screened simultaneously, e.g., using a high-throughput screening (HTS) process. Instead of or in addition to high-throughput screening (HTS), elution assays may be used to eliminate potential HIC protocol parameters.

[0066] Advantageously, these screening techniques and assays can result in significant time savings in identifying purification schemes suitable for use in large-scale purification processes, for example, by optimizing a HIC unit operation. For example, an HTS process performed according to the present disclosure can be about 10 times faster, 50 times faster, 60 times faster, 70 times faster, or even faster than conventional means of identifying regeneration / utility problems in chromatographic protocols for one or more unit operations, including HIC, ion exchange, affinity, and others.

[0067]

[0067] The evaluation method according to the present disclosure may include filling a well, e.g., a filter plate well, with a volume of chromatography media intended for use in a potential purification scheme. The filter plate well may have a volume of, e.g., less than 5 mL, e.g., less than 4 mL, less than 3 mL, or less than 2 mL. In some embodiments, the filter plate well may have a volume of about 1 mL, about 0.8 mL, about 0.5 mL, or any other suitable volume. The filter plate well may be fitted with a filter having a suitable mesh size, e.g., between about 0.5 and about 1.5 microns, e.g., about 0.8 microns, about 1.0 microns, or about 1.2 microns mesh size. The filter mesh size may depend on the size of the resin beads present in the chromatography media used in the protocol. The size of such chromatography resin beads can be, for example, between about 40 microns and about 120 microns, for example, between about 50 microns and about 100 microns, between about 60 microns and about 90 microns, between about 80 microns and about 90 microns, about 70 microns, about 80 microns, about 90 microns, about 100 microns, or about 110 microns. The amount of chromatography medium loaded into the wells can vary. For example, the amount of chromatography medium can range, for example, from about 2.0 μL to about 50.0 μL, for example, about 10.0 μL, about 20.0 μL, about 30.0 μL, or about 40.0 μL. In some methods according to the present disclosure, a filter plate containing multiple wells can be loaded with multiple different chromatography media to simultaneously evaluate multiple protocols in an array. This can be used for chromatography steps in purification schemes, including HIC, ion exchange, affinity, and others.

[0068] A volume of loading material may be loaded into the loaded filter plate well (or into each loaded filter plate well if multiple protocols are evaluated simultaneously). The loading material may contain the target molecule that has undergone some initial purification process, such as affinity or ion exchange chromatography. The loading material may be used in accordance with the present disclosure to test a unit operation, such as HIC. When multiple conditions are evaluated simultaneously for a single unit operation, the loading material used in different wells may contain different target molecules. The loading material may be titrated to a protocol-specific pH. The approximate concentration of the target molecule in the loading material may be adjusted to any appropriate unit operation-specific concentration. In some embodiments, the volume of the loading material may correspond to a fraction of the loading mass used in a full-scale protocol, e.g., 1 / 2, 1 / 5, 1 / 8, 1 / 10, 1 / 20, 1 / 50, 1 / 100 or less of the loading mass (e.g., the mass of the target molecule in the loading material) used in a full-scale protocol.

[0069]

[0069] The method for evaluating a protocol for a unit operation may further include performing elution and wash steps suitable for use in a large-scale process (e.g., including the use of RODI, 1N sodium hydroxide, and / or 5 mM sodium hydroxide), followed by a stripping step using a caustic or chaotropic agent, such as 6N guanidine HCl or 6N urea, or a solvent, such as 20% ethanol. The elution / wash step may be performed, for example, with an elution buffer titrated to a protocol-specific pH. When evaluating multiple protocols for a unit operation, elution buffers exhibiting different protocol-specific pH values ​​may be used in different wells in a single array. The elution step may include, for example, exposing the chromatography media loaded into the filter plate wells to a gradient of elution buffer (starting with a relatively high concentration and ending with a concentration of 0). In another embodiment, the elution step may involve exposing the loaded chromatographic medium to a buffer having an initial concentration of kosmotropic salt (e.g., citrate 500 mM, 400 mM, 300 mM, 200 mM, etc.) that gradually / linearly decreases in buffer concentration to 0. In some embodiments, a pseudo-gradient elution may be performed, in which the loaded chromatographic medium is exposed to separate volumes of elution buffer having linearly decreasing concentrations from the starting concentration (e.g., 300 mM) to 0 over multiple steps (e.g., 4, 5, 6, 7, 8, more or fewer steps).

[0070]

[0070] The first step may include any process intended for testing as a unit operation protocol. Generally, the first step may include applying a solution deemed suitable for use in large-scale and repeated operations (e.g., a solution that does not present safety or toxicity concerns). For example, the first step may include one or more washes of RODI and / or 1N NaOH, each applied one or multiple times, in succession or alternating order. The second step may include any solution intended to strip any residual material bound to the chromatographic medium after the unit operation protocol being evaluated is completed. Such regeneration processes are described elsewhere herein, but generally may include a chaotropic agent, such as 6N guanidine HCl or 6N urea, or a solvent, such as 20% ethanol.

[0071]

[0071] Evaluation methods according to the present disclosure may include, for example, measuring the amount of target molecules recovered during the washing / elution step and the stripping step. These results may be compared between various chromatographic media. It may be preferable for a relatively large percentage of the target molecules to be recovered during the washing / elution step (i.e., during the HIC protocol being tested) rather than during the stripping step (i.e., rigorous stripping of the chromatographic media).

[0072]

[0072] The evaluation method according to the present disclosure may further comprise determining the recovery of the target molecule during the stripping step as a percentage of the total target molecules recovered during the unit operation protocol being tested. If the percentage of recovery of the target molecule during the stripping step is above a predetermined threshold, the unit operation protocol may be predicted to have the potential to cause reproducibility / reusability problems when scaled up and / or repeated multiple times. If the percentage of recovery of the target molecule during the stripping step is at or below a predetermined threshold, the unit operation protocol may be predicted to not cause reproducibility / reusability problems when scaled up and / or repeated multiple times. The predetermined threshold may be any empirically determined threshold indicative of the amount of residue remaining bound to the chromatography media after a unit operation, e.g., a HIC protocol. In some embodiments, the predetermined threshold may be, for example, between about 1% and about 10%, for example, between about 3% and about 7%, for example, about 4%, about 5%, or about 6%.

[0073] In embodiments where multiple chromatographic protocols are evaluated simultaneously, the above calculation of percentage recovery of target molecule can be determined at once for multiple chromatographic runs to generate an initial impression of which protocols may be suitable or prioritized for further use, testing, investigation, or development. Protocols for further study may include wells where a normalized percentage recovery attributable to the stripping step may be 1% or less, 3% or less, 5% or less, 7% or less, or 10% or less.

[0074] In some embodiments, methods for evaluating chromatography protocols according to the present disclosure, such as protocols for HIC unit operations, may be performed in the early stages of developing a purification process. For example, multiple HIC protocols may be evaluated as described herein (e.g., high-throughput screening and / or elution assays), and HIC protocols predicted to pose regenerablility / reusability issues may be eliminated or deprioritized from further study. Chromatography protocols not predicted to pose regenerablility / reusability issues may be subjected to further testing (e.g., full-scale testing) or study to, for example, maximize yield, minimize impurities, ensure that they meet internal and external quality control guidelines, and evaluate repeatability and longevity (e.g., whether they do not cause column discoloration or other undesirable effects after 10, 25, 50, 75, 100 or more cycles).

[0075] In some embodiments, methods according to the present disclosure may advantageously prevent or reduce discoloration of regenerated columns, media, and / or equipment that may otherwise occur after one or more uses (see, e.g., Examples 6 and 9 discussed herein). In some embodiments, methods according to the present disclosure may advantageously aid in early identification of protocols for chromatographic unit operations that may present regeneration / serviceability challenges, thus saving time and expense that may be incurred in developing a complete purification scheme, only to later find that a protocol for that chromatographic step presents such a problem.

[0076]

[0076] Reference is now made to certain figures. Figure 1 shows a method 100 of regenerating a chromatography column according to an embodiment of the present disclosure. According to step 102, a first load mass may be applied to the hydrophobic interaction chromatography column. According to step 104, the protein of interest may be collected from the hydrophobic interaction chromatography column. According to step 106, a single alkaline regenerating solution may be applied to the chromatography column to remove materials bound to the hydrophobic interaction medium in the column.

[0077] According to step 102, a first load mass may be applied to the hydrophobic interaction chromatography column. The load mass may include the target molecule (e.g., a polypeptide) as well as residual components, such as host cell proteins, cell debris, etc. According to step 104, the protein of interest may be collected from the hydrophobic interaction chromatography column. This may be done, for example, in a washing step or an elution step. According to step 106, a single alkaline regenerating solution may be applied to the chromatography column to remove materials bound to the hydrophobic interaction medium in the column. The single alkaline regenerating solution may have one or more of the properties described above. EXAMPLES

[0078] Example 1

[0079] The amount of non-esterified free fatty acids ("NEFA") in several sample solutions was measured after incubation with polysorbate 20 ("PS20"). The presence and amount of NEFA in a sample is interpreted as an indication of PS20 degradation caused, for example, by impurities in the sample, such as host cell proteins. The first sample was taken from the HIC load mass. Five additional samples were taken from the HIC pool after the following 1, 2, 3, 5, and 10 cycles. All samples were incubated for the same time. As shown in Table 1 below, from cycle 1 to cycle 5, PS20 degradation was calculated to be a negative percentage equivalent to the negative control. A negative PS20 degradation percentage corresponds to no detectable NEFA and, consequently, no detectable lipase activity. NEFA was detectable between cycles 5 and 10, indicating an increase in lipase activity. This data shows that lipase activity can increase as a function of cycling. [Table 1]

[0080] Example 2

[0081] FIG. 2 shows the results of the analysis of HIC media (Capto) in various states after exposure to use or regeneration solutions, as described in more detail below. TM Blot analysis of Phenyl (High Sub) (GE Healthcare Life Sciences) is shown. [Table 2]

[0082] As can be seen from FIG. 2, dark areas are visible for each used column except for the column contacted with 6N guanidine HCl (column F). The column representing untreated media (column A) also does not show dark areas. This data indicates that 6N guanidine HCl is capable of removing residual media during regeneration of a chromatography column when compared to other solutions. 6N guanidine HCl is therefore utilized as a stripping agent and as an agent that may be used subsequently to other stripping / regenerating agents to evaluate the effectiveness of such other agents.

[0083] Example 3

[0084] FIG. 3 shows the results of the analysis of HIC media (Capto) in various states after exposure to use or regeneration solutions, as described in more detail below. TM Blot analysis of Phenyl (High Sub) is shown. [Table 3]

[0085] Table 3 lists the type of media used and which regenerant, if any, the media was exposed to. As can be seen from Figure 3, the regeneration paradigm including RODI, 1.0N NaOH, RODI, and 20% ethanol (used in media B and C) was not as complete in its ability to remove residues from the media as 6N guanidine HCl (D) was in its ability to remove residues from the media.

[0086] Example 4

[0087]

[0087] Figure 4 shows overlaid UV chromatograms depicting five sanitization procedures after harvest of monoclonal antibody mAb 1 in process. Each sanitization procedure included a first 0.5N sodium hydroxide flush of 2 column volumes (A), followed by a pause, then a second 0.5N sodium hydroxide flush of 1 column volume (B). Sanitization was considered complete at time C, after which a water for injection ("WFI") flush of 2 column volumes was performed (D). As can be seen in Figure 4, the first sodium hydroxide flush (A) produces a high absorbance in the initial part of the flush, which correlates with the removal of a large amount of impurities. The maximum absorbance seen during the HIC elution (regeneration) was 2.4 AU, whereas the maximum absorbance seen during the sanitization cycle of Figure 4 was approximately 1.4 AU.

[0088] Example 5

[0089] FIG. 5 shows the results of the analysis of HIC media (Capto) in various states after use or exposure to a stripping solution, as described in more detail below. TM Blot analysis of phenyl (High Sub) is shown. Specifically, the HIC media used were exposed to decreasing concentrations of guanidine. [Table 4]

[0090] As can be seen in FIG. 5, the use of 6N guanidine HCl (D) removed most of the residues from the HIC media, while solutions with lower concentrations of guanidine, and a solution of 20% ethanol were less effective at removing residues from the HIC media.

[0091] Example 6

[0092] FIG. 6 shows the Capto TMTwo columns containing Captophenyl (High Sub) (GE Healthcare Life Sciences) are shown. The column on the left was exposed to 49 cycles of HIC to purify the monoclonal antibody mAb 2. Each cycle included regeneration of the column in the following order: RODI, 1N sodium hydroxide, RODI, and 20% ethanol. After the 40th cycle, a yellow band was identified at the bottom of the column. The column on the right, as a comparison, contains untreated Capto TM Representative of Phenyl (High Sub) HIC media. Discoloration in the left column can be an indication of insufficient regeneration.

[0093] Pools were collected from cycles 1 and 49 and analyzed for lipase activity and the presence of host cell proteins (HCPs). There were no significant trends in lipase activity or HCP values ​​between cycles 1 and 49.

[0094] Example 7

[0095]

[0095] Figures 7A and 7B show chromatograms of cycles 2 and 49, respectively, performed on the left column as described with respect to Example 6. Figures 7A and 7B are annotated as follows: [Table 5]

[0096] In both cycle 2 and cycle 49, RODI was not an effective stripping solution, as indicated by the absence of peaks after C or C' (markers X and X'). The introduction of 1N NaOH eliminated peak P 1 (Cycle 2) and P 3 (Cycle 49) occurred, which means that the 1N NaOH was at least partially effective as a stripping solution. The introduction of the second RODI strip removed some additional impurities, resulting in the peak P 2 (Cycle 2) and P 4(Cycle 49). Introduction of the 20% ethanol solution did not produce an additional peak. This data from both cycles indicates that RODI is not an effective stripping solution when used before sodium hydroxide.

[0097] Example 8

[0098]

[0098] Two loading masses, each containing a target monoclonal antibody, were subjected to a hydrophobic interaction chromatography process. In the first process, after loading, washing and elution of the target monoclonal antibody mAb 3 from the first loading mass, the chromatography column was subjected to a 1N sodium hydroxide stripping solution, followed by a RODI strip, and a 20% ethanol strip. In the second process, after loading, washing and elution of the target monoclonal antibody mAb 4 from the second loading mass, the chromatography column was subjected to a RODI strip, followed by a 1N sodium hydroxide strip, another RODI strip, and a 20% ethanol strip. Figure 8A shows a chromatogram for the first process, and Figure 8B shows a chromatogram for the second process. Each chromatogram is annotated as follows: [Table 6]

[0099] After the first RODI strip (marker X'), shown at marker D' in Figure 8B, there is no peak, which is comparable to the lack of a peak at the position shown by marker X in Figure 8A (no first RODI strip performed). Thus, the decrease in conductivity of the first RODI strip applied in the first process did not cause the removal of any appreciable amount of material from the chromatography column.

[0100] Example 9

[0101]

[0101] The effectiveness of 6N guanidine HCl as a stripping solution and as a potential solution for removing the discoloration on the left column shown in Figure 6 was further evaluated. The column was subjected to the protocol described in the table below, during which the chromatogram shown in Figure 9 was produced. [Table 7] Each solution was moved through the column at a rate of 200 cm / hr in either the downflow direction (i.e., the same direction that the HIC purification process flows) or the upflow direction (i.e., opposite to the downflow, or "backwards" through the column). A second application of 6N guanidine HCl (indicated by an asterisk) was carried out in the column for approximately 16 hours.

[0102] As shown in the chromatogram of FIG. 9, the first introduction of RODI resulted in peak P 1 The first strip of 6N guanidine HCl after the first introduction of RODI resulted in a high peak P 2 There were no peaks associated with the second strip of 6N guanidine HCl that was held overnight in the column before flowing through. This likely indicates the effectiveness of the first strip of 6N guanidine HCl in removing residues bound to the column. However, after the entire cleaning protocol the column remained discolored (as shown in Figure 6).

[0103] Example 10

[0104]

[0104] The regeneration paradigm was analyzed in detail. Figure 10A shows the regeneration paradigm of Capto TM Chromatograms of the HIC procedure using Phenyl (High Sub) media (GE Life Sciences) to purify monoclonal antibody mAb 4. The HIC procedure involving the regeneration paradigm included the following steps: [Table 8]

[0105]

[0105] Referring to FIG. 10A, peak P 1 Following the introduction of 1N sodium hydroxide (E), peak P 2 coincided with the second RODI strip (F). Peak P 3 This was followed by 6N guanidine HCL induction (I).

[0106] FIG. 10B shows peak P 1 The first RODI strip (D) did not produce any detectable absorbance. The 1N NaOH strip (E) produced no detectable absorbance at peak P 1 This appears to result in immediate and early removal of the residue from the column, as indicated by the presence of peak P 1 appeared to become baseline as conductivity increased. It is hypothesized that the initial RODI strip (D) may cause some residue to bind more tightly to the column rather than facilitating its removal. It is further hypothesized that the elution of residue from the column caused by sodium hydroxide is primarily driven by pH, but as the concentration of sodium hydroxide (a weak kosmotrope) increases, the residual protein may bind more tightly to the HIC medium as solution conductivity increases.

[0107] Example 11

[0108]

[0108] The elution of residues from the spent HIC media was observed as a function of sodium hydroxide concentration. Figure 11 shows a chromatogram of the process after loading and washing the HIC column to collect the monoclonal antibody mAb 4 (in section A), a 20 CV gradient of mixed RODI and sodium hydroxide was loaded onto the column, starting with RODI only and gradually increasing the concentration of sodium hydroxide to a maximum concentration of 1N sodium hydroxide (section B). One distinct peak P elutes upon passing ∼5 mM sodium hydroxide through the column. 1A second 20 CV gradient was performed and loaded onto the column, starting with RODI and a maximum concentration of 1N sodium hydroxide, gradually decreasing the concentration of sodium hydroxide to 0 (section C). No further peaks were observed during this second gradient. Finally, 6N guanidine HCl solution was flushed through the column at mark D. During the passage of 6N guanidine HCl through the column, a small peak P 2 The area under the curve (AUC) of each peak was calculated by integrating the 280 nm UV absorbance. Compared to the AUC of the 6N guanidine HCl strip in the control treatment, which was calculated to be 13,305 mL*mAU, the peak P 2 was calculated to have 1,160 mL*mAU. 2 showed a 91.3% reduction in size when compared to controls.

[0109]

[0109] This process demonstrated that a maximum amount of bound material eluted from the column when .about.5 mM sodium hydroxide was passed through the column, leaving a relatively small amount of residual media which eluted with 6N guanidine HCl.

[0110] Example 12

[0111] Sodium hydroxide solutions with various concentrations (1000 mM, 500 mM, 100 mM, 50 mM, 25 mM, 10 mM, and 5 mM) were applied in separate two-solution regeneration processes, each performed after loading and washing the HIC column. Each regeneration process included sodium hydroxide solution as the first regeneration solution and 6N guanidine HCl solution as the second regeneration solution. Chromatograms for the regeneration processes were generated and are overlaid in FIG. 12. The sodium hydroxide solution in each regeneration process produced a first peak, shown in the peak group labeled A. The 6N guanidine HCl solution in each regeneration process produced a second peak, shown in the peak group labeled B. It was determined that the regeneration process containing 5 mM NaOH produced the largest "A" peak (indicating the largest amount of retained eluted with application of sodium hydroxide solution) and the smallest "B" peak (indicating the smallest amount of retained eluted with application of guanidine HCl). Thus, in the range of sodium hydroxide solutions tested, 5 mM sodium hydroxide solution was the most effective at regenerating the HIC column (i.e., removed the most bound material from the column). The higher the sodium hydroxide concentration, the more residual mass remained on the column for removal by the 6N guanidine HCl solution. It was hypothesized that increasing pH would facilitate elution of the residual from the HIC column, while increasing conductivity would decrease elution of the residual by strengthening the bond between the residual and the HIC media.

[0112] Example 13

[0113]

[0113] Capto TMA one-way statistical analysis of variance was performed on the areas under the curve (AUC) of chromatographic peaks resulting from regeneration treatments following collection of mAb 4 from a HIC column prepared with Phenyl (High Sub) media (GE Healthcare Life Sciences). As shown in Figures 13A and 13B, regeneration treatments were performed with control (A), RODI (B), and various concentrations of sodium hydroxide solution (C-L). Each regeneration treatment included a stripping solution (AUC analyzed in Figure 13A), followed by 6N guanidine HCl solution (AUC analyzed in Figure 13B). All-pair Turkey-Kramer tests were also performed for each analysis to show statistical significance.

[0114] As shown in Figures 13A and 13B, the treatments associated with 0.5 mM NaOH and 1 mM NaOH regeneration solutions showed the highest AUC values ​​(circled in area 1300) for the peaks occurring during the flow-through of these regeneration solutions, indicating that these regeneration solutions cause more effective removal of materials from the HIC column. The treatments associated with 0.5 mM NaOH, 1 mM NaOH, and 5 mM NaOH regeneration solutions showed the lowest AUC values ​​(circled in area 1350 in Figure 13B) for the peaks occurring during the flow-through of the 6N guanidine HCl solution following the regeneration solutions, again confirming that these regeneration solutions cause more efficient removal of materials from the HIC column, leaving less to be removed by the 6N guanidine HCl. Thus, solutions with sodium hydroxide concentrations ranging from 0.5 mM to 5 mM NaOH were shown to be effective for regenerating the HIC column.

[0115] Example 14

[0116]

[0116] The regeneration process using sodium hydroxide solution was compared to the regeneration process using sodium chloride solution. After collection of monoclonal antibody mAb 5 from the HIC column, the column was regenerated with sodium hydroxide having a concentration of 3 mM, 5 mM, or 7 mM, or with sodium chloride having a concentration of 5 mM, 8 mM, or 11 mM. The pH and conductivity of each regeneration solution were also noted. The sodium hydroxide solutions all showed a pH greater than 11, while the sodium chloride solutions all showed a pH between 5.5 and 6.5. The solution conductivities were comparable. For each process, 6N guanidine HCl solution was applied to each column after the regeneration solution. Chromatograms were generated for each process, all of which are overlaid in Figure 14. The AUC was calculated for the peaks associated with the regeneration solution flow-through and the 6N guanidine HCl flow-through. The solutions and AUC are listed in the table below. [Table 9]

[0117] As shown in this data, the flow-through of sodium hydroxide solution exhibited substantially higher AUC values ​​than the sodium chloride solution. Similarly, the flow-through of 6N guanidine HCl after sodium hydroxide solution exhibited substantially lower AUC values ​​than the flow-through of 6N guanidine HCl after sodium chloride solution. In FIG. 14, the peaks produced by the flow-through of sodium hydroxide are indicated by marker A, and the peaks (or lack of peaks) produced by the flow-through of sodium chloride are indicated by marker B. Similarly, the peaks produced by the flow-through of 6N guanidine HCl after sodium hydroxide and the flow-through of 6N guanidine HCl after sodium chloride are indicated by markers A' and B', respectively. As shown in FIG. 14, sodium hydroxide solution was a more effective stripping agent than sodium chloride solution.

[0118] Example 15

[0119] Potential cleaning / regenerating solutions were tested on columns that had been subjected to 50 cycles of HIC to purify monoclonal antibody mAb 6. The columns exhibited discoloration near the top of the column bed (columns A, B, and C) as shown in Figure 15. Column A was flushed with 2 CV of 0.5 M EDTA, column B was flushed with 2 CV of 0.5 M acetic acid, and column C was used as a control. Both solutions were ineffective in reducing the browning / discoloration.

[0120] Example 16

[0121] Three sodium hydroxide solutions (2 mM, 5 mM, and 10 mM) were used as regeneration solutions following HIC purification of monoclonal antibody mAb 6. The effectiveness of each sodium hydroxide solution in regenerating the HIC media used in the purification process was characterized by the size of the chromatogram peak associated with the 6N guanidine HCl strip following application of each sodium hydroxide solution. A larger AUC associated with the guanidine strip peak indicated that a greater amount of residual was left by the sodium hydroxide solution preceding the strip, and conversely, a smaller AUC associated with the guanidine strip peak indicated that a lesser amount of residual was left by the sodium hydroxide solution preceding the strip, and thus, the sodium hydroxide regeneration solution was more effective. Figure 16 shows a graph showing the guanidine strip peak AUC as a function of sodium hydroxide concentration. All three sodium hydroxide solutions tested showed more effective regeneration (i.e., smaller guanidine strip peaks) than the default cleaning paradigm, which included the sequence RODI, 1N sodium hydroxide, RODI, 20% ethanol, and RODI. The 5 mM sodium hydroxide solution had the lowest guanidine strip peak area. Based on the curve extrapolated from the data points, it is possible that the 7 mM sodium hydroxide regeneration solution may produce an even lower guanidine strip peak area.

[0122] Example 17

[0123]

[0123] The first regeneration process, designated as control, was used on the HIC column after collection of monoclonal antibody mAb 5 from the column. The process was used to generate a chromatogram. A number of solutions were used, starting with 1N sodium hydroxide, followed by RODI, 20% ethanol, RODI, and 6N guanidine HCl, in that order. The chromatogram peak corresponding to the flow-through of 6N guanidine HCl was used as a measure of the effectiveness of the regeneration process. The chromatogram is shown in Figure 17. Markers on the chromatogram indicate the following events: [Table 10] The AUC of the peak corresponding to the flow-through of 6 N guanidine HCl solution was calculated to be 7,390 mL*mAU.

[0124] After collection of mAb 5 from the HIC column, a second regeneration process containing 5 mM sodium hydroxide was used and the chromatogram was generated and shown in Figure 18. A number of solutions were used in the following order starting with 5 mM sodium hydroxide, followed by RODI, 20% ethanol, RODI, 5 mM sodium hydroxide, RODI, 6N guanidine HCl, and 0.1N sodium hydroxide. The AUC corresponding to the flow-through of each solution was calculated from the chromatogram and the results are listed in the table below. [Table 11]

[0125] As shown in FIG. 18 and reflected by the AUC values ​​in the table above, the initial 5 mM NaOH flow-through showed the highest AUC by the largest difference (peak A). Solutions applied to the column after the initial 5 mM NaOH solution provided minimal additional material removal from the HIC column, as indicated by the relatively small corresponding AUC values. The second largest AUC value was associated with the 6N guanidine HCl flow-through, but at 889 mL*mAU, it was less than 30 times lower than the AUC value associated with the initial 5 mM NaOH flow-through. Furthermore, the smaller AUC value of the 6N guanidine HCl peak during this regeneration process compared to the AUC value of the 6N guanidine HCl peak during the control process shown in FIG. 17 (7,390 mL*mAU) indicated that the initial 5 mM NaOH solution provided substantially improved regeneration of the HIC column when compared to the control run. RODI, 20% ethanol, 6N guanidine HCl, and 0.1N NaOH offered minimal additional benefit to HIC regeneration when used after the 5 mM NaOH solution.

[0126] Example 18

[0127] Six mixtures, each containing a different target molecule (e.g., a target monoclonal antibody) and containing different concentrations of citrate in the loading buffer, were run on Capto TM The monoclonal antibodies were subjected to HIC in columns containing phenyl (High Sub) media (GE Life Sciences). After elution of each monoclonal antibody, the HIC column used was subjected to a gradient starting from a solution containing no sodium hydroxide (pure RODI) to 1N sodium hydroxide, then a volume of RODI and sodium hydroxide in the reverse direction gradient (from 1N sodium hydroxide back to pure RODI). Finally, each process was terminated with a load of 6N guanidine HCl and collection of the flow-through. The table below shows the pH and citrate concentration in each load mixture. [Table 12]

[0128] For each process, a chromatogram was generated; a series of chromatograms are shown in FIG. 19. As shown, each chromatogram A-F contained peaks (A', B', C', D', E', F') corresponding to the elution of material bound to the HIC media with the flow-through of approximately 5 mM NaOH. The subsequent guanidine HCl flow-through peaks were extremely small or absent. Thus, it was shown that the effectiveness of the regeneration solution is not limited to the use of one monoclonal antibody.

[0129] Example 19

[0130]

[0130] A number of HIC protocols with different conditions were evaluated to assess whether such protocols could impose reproducibility / serviceability issues. TM Wells of an Advance 1 mL filter plate, 1.2 μm Supor membrane, part number 8130, Pall Corporation) were filled with 0.02 μL of various HIC media as follows: [Table 13]

[0131]

[0131] Aliquots of loading material containing one of three target antibodies (mAb 1, mAb 2, mAb 3) were prepared and adjusted to a concentration of 0.33 g / L when mixed with HIC media, with a target concentration of 5 g / L. For each of the three target antibodies, the aliquots of loading material were titrated against different pHs (4.5, 6.25, or 8.0) with 2 M acetic acid or 2 M Tris base to prepare a total of nine aliquots, each containing one of the three target antibodies and representing one of the three different pH values.

[0132] Each of the three columns of wells filled with one media type was subjected to a purification protocol at a different pH (4.5, 6.25, or 8.0) to generate a series of protocols using various combinations of media and pH. The rows of wells in each column were grouped such that each group of rows was subjected to a protocol for a different target antibody (mAb 1, mAb 2, or mAb 3). To run each protocol at each pH, ​​an aliquot of loading material containing the target antibody at the corresponding pH was used for each target antibody, as well as an equilibration buffer of 40 mM Tris, 300 mM citrate at the corresponding pH.

[0133]

[0133] The following steps are performed simultaneously on the array. 1. Equilibrate wells loaded with the various HIC resins three times with equilibration buffers of each pH. 2. Add loading material containing the desired target antibody at each pH to each well and incubate for 1 hour. 3. Spin the plate at 1100 rpm. 4. Collect the flow-through (i.e. components that are not bound to the medium during incubation). 5. For each protocol being tested, wash the wells twice with equilibration buffer of the respective pH. 6. Perform pseudo-gradient elution with equilibration buffer of each pH. Each well is exposed to equilibration buffer in seven replicates, with the citrate concentration decreasing linearly from 300 mM to 0 mM over all seven replicates (42.9 mM increments per replicate). 7. Wash wells twice with RODI and twice with 1N sodium hydroxide. 8. Spin the plate at 1100 rpm. 9. Strip wells twice with 6N guanidine HCl solution. 10. Spin the plate at 1100 rpm.

[0134] For each well, a chromatogram of the target polypeptide in the material removed from the well (flow-through, eluent, wash, etc.) was generated. To analyze the results, each chromatogram was divided into three zones: the first zone contained the mass of the target polypeptide observed in the material removed during steps 2, 3, and 4 (flow-through, wash, and elution), the second zone contained the mass of the target polypeptide observed in the material removed during steps 5, 6, 7, 8 (using RODI and 1N sodium hydroxide), and the third zone contained the mass of the target polypeptide observed in the material removed during steps 9 and 10 (using 6N guanidine HCl). The chromatograms were analyzed using a pH of 6.25 and three different HIC media (TOYOPEARL TM Hexyl-650C, Phenyl Sepharose 6 Fast Flow (High Sub), and POROS TM Three example chromatograms, separated into three zones, generated from a protocol for purifying the target antibody mAb 1 with ethyl) are shown in Figures 20A-20C.

[0135]

[0135] The comparison shows that the protocols and analyses performed on the test wells match those performed on the large scale columns with a statistically significant accuracy of 98%.

[0136] Example 20

[0137]

[0137] The aggregate collection of data using the high-throughput screening techniques described herein allows for the development of predictive functions that can inform the development of HIC protocols of improved efficiency and yield. For example, boundary functions may be plotted that describe the relationship between a number of parameters (e.g., pH, elution buffer citrate concentration, load mass, HIC media choice) and either the efficiency or yield of the protocol.

[0138] FIG. 21A shows the results of a given antibody and phenyl sepharose at a loading of 100 g per liter of medium. TM1 is a plot of the boundary function for elution buffer citrate concentration and pH versus predicted yield of the HIC protocol based on the total collection of high-throughput screening data for the medium. The shaded area corresponds to the combination of HIC protocol parameters that results in a predicted yield of less than 90% of the theoretical yield. The boundary function is based on the total collection of high-throughput screening data for the medium. TM This provides information on which citrate and pH parameters should be considered for HIC protocols involving media. Combinations of pH and citrate concentrations outside the shaded region are not suitable for a given antibody and phenyl sepharose. TM While the available HIC protocol parameters for the medium, the combinations of pH and citrate concentration within the shaded area are excluded parameters.

[0139] FIG. 21B shows the results of the antibody-specific antibody and CaptoProtein at a loading of 100 g per liter of medium. TM Figure 1 is a plot of the boundary function for elution buffer citrate concentration and pH versus predicted yield of the HIC protocol based on the total collection of high-throughput screening data on Phenyl (High Sub) chromatography media. The shaded area corresponds to the combination of HIC protocol parameters that results in a predicted yield of less than 90% of the theoretical yield. The boundary function is consistent with the predicted yield for a given antibody and Capto TM This provides information on which citrate and pH parameters should be considered for HIC protocols involving Phenyl (High Sub) media. Combinations of pH and citrate concentrations outside the shaded region are suitable for a given antibody and Capto TM Available HIC protocol parameters for Phenyl (High Sub) medium, while combinations of pH and citrate concentration within the shaded area are excluded parameters.

[0140] In addition to the boundary functions described above, data collected from high-throughput screening may allow the development of a transfer function or other mathematical model that may aid in the design of HIC protocols. For example, a transfer function may be regressed to relate data from an elution assay, a high-throughput screen, or a laboratory-scale HIC protocol to a full-scale HIC protocol. For example, for a set of HIC protocols that include predicted yields (e.g., predicted yields by small-scale assays or high-throughput screening), the actual yields may be determined for each HIC protocol through full-scale chromatography. The relationship between predicted and actual yields may be regressed to improve the predictive model. Future predicted yields may be calculated, at least in part, based on the regression relationship (e.g., transfer function) when applied to data from an elution assay, a high-throughput screen, or a laboratory-scale HIC protocol.

[0141]

[0141] One or more transfer functions, boundary functions, and / or predictive models may be combined to develop a dynamic predictive model. With reference to FIG. 22, a dynamic predictive model is shown. The dynamic predictive model calculates how changes to one or more HIC protocol parameters (e.g., pH, citrate concentration, load mass, chromatography resin) affect the quantified characteristic of the HIC protocol. For example, in the example shown in FIG. 22, the resulting protocol parameters selected are a pH of 6, a citrate concentration of 30 mM, a load mass of 100 g per liter of HIC media, and a resin C (e.g., phenyl sepharose). TMThe model then shows how each of these parameters affects the predicted yield, a high molecular weight fraction, and a pool host cell protein concentration of the eluate collected using the HIC protocol with the selected parameters. As shown in FIG. 22, the selected parameters result in approximately 95% of the predicted yield, a high molecular weight fraction of approximately 1.3, and a pool host cell protein concentration of approximately 22.5 ppm. These quantified properties may be used to evaluate the HIC protocol and may provide information on how the protocol parameters affect the product of the HIC protocol. Values ​​for the quantified properties calculated by the dynamic model may be updated in real time as the protocol parameters are modified.

[0142] In some embodiments, an overall desirability may also be calculated as a composite of the quantified characteristics of the protocol (e.g., a composite of predicted yield, high molecular weight fraction, and pool host cell protein concentration). The desirability calculation may be based on a weighting of the quantitative characteristics of the HIC protocol. For example, changes to the HIC protocol that affect the yield of the protocol may be more important than changes that affect efficiency. The dynamic prediction model may take into account the relative importance of the quantitative measurements and assign weights to different measurements so that they affect the overall desirability unequally. In some embodiments, the dynamic prediction model may be updated as additional chromatographic data (e.g., data from small-scale assays, high-throughput screens, and full-scale chromatographic runs) is collected and integrated.

[0143] Example 21

[0144]

[0144] A number of HIC protocols involving combinations of different target molecules and HIC media at various pHs were tested in gradient elution assays to determine whether such combinations might pose regeneration / serviceability issues and whether any of the target molecule and HIC media combinations should be excluded from further HIC protocol development.

[0145]

[0145] 96-well filter plate (AcroPrep TM Wells of an Advance 1 mL filter plate, 1.2 μm Supor membrane, part number 8130, Pall Corporation) were loaded with 0.02 μL of the various HIC media. Aliquots of loading material containing the target molecules were prepared and adjusted to a concentration of 0.33 g / L, targeting a concentration of 5 g / L when mixed with the HIC media. For each of the three target antibodies, the loading material aliquots were titrated against several different pHs (e.g., 4.5, 6.25, or 8.0) with 2 M acetic acid or 2 M Tris base to prepare several aliquots, each containing the target antibody and representing a different pH value.

[0146]

[0146] Each well of a 96-well plate filled with one media type was subjected to the HIC protocol at a different pH (4.5, 6.25, or 8.0), resulting in a series of protocols run with various combinations of media and pH.

[0147]

[0147] The following steps are performed simultaneously on the array. 1. Equilibrate wells loaded with the various HIC resins three times with equilibration buffers of each pH. 2. Add loading material containing the desired target molecule at each pH to each well and incubate for 1 hour. 3. Spin the plate at 1100 rpm. 4. Collect the flow-through (eg, containing components that have not bound to the medium during incubation). 5. For each protocol being tested, wash the wells three times with equilibration buffer of the respective pH. 6. Perform mock elution: expose each well to elution buffer in seven replicates, spin the plate at 1100 rpm, and collect the eluate after each replicate. 7. Wash the wells twice with NaOH. Different wells of the array may use different concentrations of NaOH. For example, two wells may contain the same chromatography medium and are loaded at the same pH, but one well uses a 5 mM NaOH wash and the other well uses a 1 N NaOH wash. After each wash, spin the plate at 1100 rpm and collect the wash. 8. Strip the wells twice with 6N guanidine HCl solution and collect the stripped material.

[0148] For each well, a chromatogram was generated of the target molecule in the material removed from the well (flow-through, eluent, wash, etc.). To analyze the results, each chromatogram was divided into three zones: the first zone contained the mass of the target molecule observed in the material removed during steps 2, 3, and 4 (flow-through, wash, and elution), the second zone contained the mass of the target molecule observed in the material removed during steps 5, 6, 7 (using RODI and NaOH), and the third zone contained the mass of the target molecule observed in the material removed during step 8 (using 6N guanidine HCl).

[0149]

[0149] Examples of chromatograms generated from elution assays for a first target molecule are shown in Figures 23A-26C. TM 24A-24C show chromatograms of an elution assay containing a first target molecule on Phenyl (High Sub) media. TM 25A-C show chromatograms of an elution assay containing the first target molecule on butyl media. TM26A-C show chromatograms of an elution assay containing a first target molecule on benzyl media, and (R) 23A, 24A, 25A, and 26A show chromatograms of elution assays with a first target molecule on a medium. Figures 23A, 24A, 25A, and 26A show chromatograms of elution assays run at a pH of 4.5, Figures 23B, 24B, 25B, and 26B show chromatograms of elution assays run at a pH of 6.25, and Figures 23C, 24C, 25C, and 26C show chromatograms of elution assays run at a pH of 8. In Figures 23A-26C, the dotted line shows a chromatogram from an elution assay with a 5 mM NaOH wash, and the solid line shows a chromatogram from an elution assay with a 1 N NaOH wash.

[0150] Examples of chromatograms generated from elution assays for a second target molecule are shown in Figures 27A-28D. Each figure in Figures 27A-28 shows three chromatograms, each from an elution assay run at a different pH. Figure 27A shows the chromatograms generated from Capto TM FIG. 27B shows chromatograms from an elution assay run on Phenyl (High Sub) media, and FIG. TM FIG. 27C shows chromatograms from an elution assay run on butyl media. TM FIG. 27D shows a chromatogram from an elution assay run on POROS Phenyl-650C media. TM FIG. 28A shows chromatograms from an elution assay run on ethyl media. TM FIG. 28B shows chromatograms from an elution assay run on TOYOPEARL Hexyl-650C media. TM FIG. 28C shows a chromatogram from an elution assay run on Butyl-650C media. TM FIG. 28D shows chromatograms from an elution assay run on benzyl media, and FIG. 28E shows chromatograms from an elution assay run on benzyl media, and FIG. (R)27A-28D show chromatograms from elution assays performed on media. In Figures 27A-28D, the dotted line shows a chromatogram from an elution assay that includes a 5 mM NaOH wash, and the solid line shows a chromatogram from an elution assay that includes a 1 N NaOH wash.

[0151] As can be seen from the chromatograms, all tested protocols that included a 1N NaOH strip contained a greater proportion of target molecular mass than comparable protocols that included a 5 mM NaOH strip, i.e., more target molecules remained bound to the column after the 1N NaOH strip compared to the 5 mM NaOH strip.

[0152]

[0152] For a given target molecule, by comparing the chromatograms of different HIC protocols, certain HIC media and / or pH can be eliminated from consideration. Using a series of elution assays to eliminate undesirable combinations of target molecules, HIC media, and pH from consideration can improve the speed of developing and testing HIC protocols. For example, a chromatogram showing that more than 5% (e.g., more than 10%) of the target molecule elutes in zone 3 can indicate that a given HIC media, pH, and target molecule combination is not suitable for integration into a HIC protocol.

[0153] In addition to using the elution assay to eliminate HIC media, pH, and target molecules from consideration, the zone 3 mass calculated from the chromatogram can be transformed through a transfer function to predict the mass of the target molecule that will elute in zone 3 during a full-scale chromatographic run. This predicted mass can also be used to eliminate combinations of HIC media, pH, and target molecule from consideration. An exemplary list of calculated zone 3 target molecule recoveries for a given target molecule in a series of HIC protocols using various combinations of HIC media and pH is shown in Table 14. [Table 14]

[0154] As can be seen in Table 14, Capto TM An elution assay containing a given target molecule on Phenyl (High Sub) media yielded a normalized percentage recovery of 38.2%. This result, when transformed through a transfer function, yields a full-scale Zone 3 recovery of 10.6%. In an embodiment where the predetermined threshold is 10%, this is higher than the threshold and therefore the target molecule, Capto TM The combination of Phenyl (High Sub) medium and a pH of 4.5 is excluded from further HIC protocol development. In some embodiments, once exclusion of a medium and pH combination for a given target molecule is warranted, that medium and pH combination may also be excluded from further protocol development involving other target molecules.

[0155]

[0155] Those skilled in the art will appreciate that the conception on which this disclosure is based may be readily utilized as a basis for the designing of other methods and systems for carrying out several purposes of the present disclosure, and therefore the claims are not to be deemed limited by the foregoing description. The present disclosure includes the following embodiments. EMBODIMENT 1 1. A method of regenerating a hydrophobic interaction chromatography column to which a loading mass has been applied, comprising the steps of: passing one or more column volumes of an alkaline solution through a hydrophobic interaction medium in the column, wherein the alkaline solution exhibits a pH between about 10 and about 14 and a conductivity between about 0.5 mS / cm and about 10 mS / cm; The method wherein substances bound to the hydrophobic interaction medium are removed. EMBODIMENT 2 2. The method of embodiment 1, wherein the alkaline solution comprises one of sodium hydroxide, potassium hydroxide, calcium hydroxide, magnesium hydroxide, or Tris. EMBODIMENT 3 2. The method of embodiment 1, wherein the alkaline solution exhibits a conductivity between about 0.8 mS / cm and about 1.6 mS / cm. EMBODIMENT 4 2. The method of embodiment 1, wherein the alkaline solution comprises a total dissolved salt concentration of between about 0.1 mM and about 10 mM. EMBODIMENT 5 2. The method of embodiment 1, wherein after removal of the material bound to the hydrophobic interaction medium, less than about 1.0% of the loaded mass remains bound to the hydrophobic interaction medium as residual mass. EMBODIMENT 6 2. The method of embodiment 1, wherein the material removed from the medium comprises a host cell protein, an aggregated protein, a lipid, a polypeptide fragment, a biomolecule, or a nucleic acid. EMBODIMENT 7 2. The method of embodiment 1, wherein the material removed from the medium does not contain bacteria or fungi. EMBODIMENT 8 2. The method of embodiment 1, wherein the method does not include contacting the hydrophobic interaction medium with a chaotropic agent or an organic solvent. EMBODIMENT 9 2. The method of embodiment 1, wherein the step of passing one or more column volumes of the alkaline solution through the hydrophobic interaction medium in the column takes from about 10 minutes to about 1 hour. EMBODIMENT 10 1. A method of regenerating a chromatography column to which a loading mass has been applied, comprising the steps of: passing one or more column volumes of an alkaline solution through a medium in the column, the alkaline solution comprising a total dissolved concentration of sodium hydroxide between about 0.5 mM and about 50 mM; The method wherein substances bound to the medium are removed. EMBODIMENT 11 11. The method of embodiment 10, wherein the medium comprises a matrix comprising ligands having between 2 and 10 hydrocarbons in an aliphatic or aromatic configuration. EMBODIMENT 12 12. The method of embodiment 11, wherein the ligand is present in the medium at a density of between about 20 and about 30 μmol per ml of medium. EMBODIMENT 13 11. The method of embodiment 10, wherein the medium does not contain a ligand containing 30 or more hydrocarbons. EMBODIMENT 14 11. The method of embodiment 10, wherein the chromatography column is not used in a mixed-mode chromatography process. EMBODIMENT 15 11. The method of embodiment 10, wherein the medium comprises a matrix comprising cross-linked agarose and a phenyl ligand. EMBODIMENT 16 11. The method of embodiment 10, wherein the method does not include contacting the medium with alcohol, ethylene glycol, or sodium chloride. EMBODIMENT 17 11. The method of embodiment 10, further comprising passing one or more column volumes of a chaotropic agent through the column after passing one or more column volumes of the alkaline solution through the column, wherein the chaotropic agent is one of 6N guanidine hydrochloride or 8N urea. EMBODIMENT 18 1. A method of preparing a chromatography column for storage, comprising: Carrying out the method of embodiment 10; and contacting the column with a storage buffer containing sodium hydroxide at a total dissolved concentration of between about 0.05M and about 0.15M; A method comprising: EMBODIMENT 19 1. A method for reusing a chromatography column, comprising: applying a first load mass to a chromatography column; performing the method of embodiment 10 on said chromatography column; and applying a second load mass to the chromatography column. Including, The method, wherein the method does not include cleaning the chromatography column. EMBODIMENT 20 1. A method for identifying a concentration of an alkaline solution for a hydrophobic interaction chromatography column regeneration solution, comprising: passing a volume of a first solution through a hydrophobic interaction medium in the column, the first solution comprising water and an alkaline solution having a concentration starting from about 0 N and increasing at a substantially constant rate to a maximum concentration; passing a volume of a second solution through a hydrophobic interaction medium, the second solution comprising water and an alkaline solution having a concentration starting from a maximum concentration and decreasing at a substantially constant rate to about 0N; and Identifying a portion of the first or second solution that, when passed through the hydrophobic interaction medium, removes substances bound to the hydrophobic interaction medium. A method comprising: EMBODIMENT 21 21. The method of embodiment 20, wherein the alkaline solution comprises sodium hydroxide and has a maximum concentration of about 1N. EMBODIMENT 22 20. The method of embodiment 18, wherein the volume of the first solution and the volume of the second solution are each about 20 column volumes. EMBODIMENT 23 1. A method for evaluating a plurality of chromatography protocols, each of the chromatography protocols comprising a chromatography medium, a protocol pH, and a target molecule; For each chromatography protocol: adding a load mass containing the target molecule to a volume of chromatography media in a filter plate well and collecting flow-through from the filter plate well, wherein the load mass indicates a protocol pH; adding a plurality of aliquots of a buffer comprising a chromatography medium to obtain an eluate from the chromatography medium, the buffer exhibiting a buffer pH, a linearly decreasing concentration of a kosmotropic salt across the plurality of aliquots, and a first amount of the target molecule being contained in the combined flow-through and eluate; adding a second solution to the chromatography medium to extract a second quantity of the target molecule from the chromatography medium; and adding a chaotropic agent to the chromatographic medium to extract a third quantity of the target molecule from the chromatographic medium; A method comprising: EMBODIMENT 24 24. The method of embodiment 23, further comprising providing a chromatographic unit operation comprising hydrophobic interaction chromatography using one of said protocols. EMBODIMENT 25 24. The method of embodiment 23, comprising simultaneously carrying out the method for multiple chromatography protocols using a filter plate. EMBODIMENT 26 24. The method of embodiment 23, wherein the loaded mass comprises less than about 20 mg of target molecule.

Claims

1. 1. A method of regenerating a hydrophobic interaction chromatography column to which a loading mass has been applied, comprising the steps of: passing one or more column volumes of an alkaline solution through a hydrophobic interaction medium in the column, the alkaline solution exhibiting a pH between about 10 and about 14 and a conductivity between about 0.5 mS / cm and about 10 mS / cm; The method wherein substances bound to the hydrophobic interaction medium are removed.

2. 10. The method of claim 1, wherein the alkaline solution comprises one of sodium hydroxide, potassium hydroxide, calcium hydroxide, magnesium hydroxide, or Tris.

3. 10. The method of claim 1, wherein the alkaline solution exhibits a conductivity between about 0.8 mS / cm and about 1.6 mS / cm.

4. 10. The method of claim 1, wherein the alkaline solution comprises a total dissolved salt concentration of between about 0.1 mM and about 10 mM.

5. 10. The method of claim 1, wherein after removal of the material bound to the hydrophobic interaction medium, less than about 1.0% of the load mass remains bound to the hydrophobic interaction medium as residual mass.

6. 10. The method of claim 1, wherein the material removed from the medium comprises a host cell protein, an aggregated protein, a lipid, a polypeptide fragment, a biomolecule, or a nucleic acid.

7. The method of claim 1 , wherein the material removed from the medium is free of bacteria or fungi.

8. The method of claim 1 , wherein the method does not include contacting the hydrophobic interaction medium with a chaotropic agent or an organic solvent.

9. 10. The method of claim 1, wherein the step of passing one or more column volumes of the alkaline solution through the hydrophobic interaction medium in the column takes from about 10 minutes to about 1 hour.

10. 1. A method of regenerating a hydrophobic interaction chromatography column to which a loading mass has been applied, comprising the steps of: passing one or more column volumes of an alkaline solution through a medium in the column, said alkaline solution comprising a total dissolved sodium hydroxide concentration of between about 0.5 mM and about 50 mM, said alkaline solution having a conductivity of between about 0.5 mS / cm and about 10 mS / cm; The method wherein substances bound to the medium are removed.

11. The method of claim 10, wherein the medium comprises a matrix comprising ligands having between 2 and 10 hydrocarbons in an aliphatic or aromatic configuration.

12. The method of claim 11, wherein the ligand is present in the medium at a density of between about 20 and about 30 μmol per ml of medium.

13. The method of claim 10, wherein the medium does not contain ligands containing 30 or more hydrocarbons.

14. 11. The method of claim 10, wherein the chromatography column is not used in a mixed-mode chromatography process.

15. The method of claim 10, wherein the medium comprises a matrix comprising cross-linked agarose and a phenyl ligand.

16. 11. The method of claim 10, wherein the method does not include contacting the medium with alcohol, ethylene glycol, or sodium chloride.

17. 11. The method of claim 10, further comprising passing one or more column volumes of a chaotropic agent through the column after passing one or more column volumes of the alkaline solution through the column, wherein the chaotropic agent is one of 6N guanidine hydrochloride or 8N urea.

18. 1. A method of preparing a chromatography column for storage, comprising: Carrying out the method of claim 10; and contacting the column with a storage buffer containing a total dissolved concentration of sodium hydroxide between about 0.05M and about 0.15M; A method comprising:

19. 1. A method for reusing a chromatography column, comprising: applying a first load mass to a chromatography column; performing the method of claim 10 on said chromatography column; and applying a second load mass to the chromatography column. Including, The method, wherein the method does not include cleaning the chromatography column.

20. 20. The method of claim 18, wherein the volume of the first solution and the volume of the second solution are each about 20 column volumes.

Images